Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 17/20 | 0.67 |
| ▸ | SULT1A1 | P50225 | 4/20 | 0.67 |
| ▸ | MAPT | P10636 | 2/20 | 0.67 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13015369 | 1.00 | APP (0.67) | APPSULT1A1MAPTTP53THRB | |
| SCHEMBL13015380 | 0.91 | APP (0.64) | APPSULT1A1MAPTTP53THRB | |
| SCHEMBL20332135 | 0.91 | APP (0.68) | APPSULT1A1MAPTTP53THRB | |
| SCHEMBL13015464 | 0.91 | APP (0.64) | APPSULT1A1MAPTTP53THRB | |
| SCHEMBL13015383 | 0.91 | APP (0.68) | APPSULT1A1MAPTTP53THRB | |
| SCHEMBL13062759 | 0.86 | APP (0.64) | APPSULT1A1MAPTTP53THRB | |
| SCHEMBL13096108 | 0.86 | APP (0.60) | APPSULT1A1MAPTTP53THRB | |
| SCHEMBL13045481 | 0.85 | APP (0.70) | APPSULT1A1MAPTTP53THRB | |
| SCHEMBL13096110 | 0.85 | APP (0.59) | APPSULT1A1MAPTTP53THRB | |
| SCHEMBL10032146 | 0.84 | APP (0.72) | APPSULT1A1MAPTTP53THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11801316-B2 | Cromolyn derivatives and related methods of imaging and treatment | THE GENERAL HOSPITAL CORPORATION (US) | 2023-10-31 | — | — | US | disclosed |
| US-11801316-B2 | Cromolyn derivatives and related methods of imaging and treatment | THE GENERAL HOSPITAL CORPORATION (US) | 2023-10-31 | — | — | US | disclosed |
| US-11666669-B2 | Cromolyn derivatives and related methods of imaging and treatment | THE GENERAL HOSPITAL CORPORATION (US) | 2023-06-06 | — | — | US | disclosed |
| US-11666669-B2 | Cromolyn derivatives and related methods of imaging and treatment | THE GENERAL HOSPITAL CORPORATION (US) | 2023-06-06 | — | — | US | disclosed |
| US-20220193087-A1 | COMBINATION THERAPIES FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS | THE GENERAL HOSPITAL CORPORATION | 2022-06-23 | — | — | US | disclosed |
| US-11110097-B2 | Combination therapies for the treatment of alzheimer's disease and related disorders | THE GENERAL HOSPITAL CORPORATION (US) | 2021-09-07 | — | — | US | disclosed |
| US-10576171-B2 | Cromolyn derivatives and related methods of imaging and treatment | THE GENERAL HOSPITAL CORPORATION (US) | 2020-03-03 | — | — | US | disclosed |
| EP-3563849-A2 | COMBINATION THERAPIES FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS | The General Hospital Corporation (US) | 2019-11-06 | — | — | EP | disclosed |
| US-10413551-B2 | Combination therapies for the treatment of Alzheimer'S disease and related disorders | THE GENERAL HOSPITAL CORPORATION (US) | 2019-09-17 | — | — | US | disclosed |
| US-10406164-B2 | Combination therapies for the treatment of Alzheimer's disease and related disorders | THE GENERAL HOSPITAL CORPORATION (US) | 2019-09-10 | — | — | US | disclosed |
| WO-2014066318-A1 | COMBINATION THERAPIES FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS | THE GENERAL HOSPITAL CORPORATION (US) | 2014-05-01 | — | — | WO | disclosed |
| US-8558003-B2 | Imaging tracers for early detection and treatment of amyloid plaques caused by Alzheimer's disease and related disorders | THE GENERAL HOSPITAL CORPORATION (US) | 2013-10-15 | — | — | US | disclosed |
| US-8558003-B2 | Imaging tracers for early detection and treatment of amyloid plaques caused by Alzheimer's disease and related disorders | THE GENERAL HOSPITAL CORPORATION (US) | 2013-10-15 | — | — | US | disclosed |
| US-7858803-B2 | Imaging tracers for early detection and treatment of amyloid plaques caused by Alzheimer's disease and related disorders | THE GENERAL HOSPITAL CORPORATION (US) | 2010-12-28 | — | — | US | disclosed |
| US-7858803-B2 | Imaging tracers for early detection and treatment of amyloid plaques caused by Alzheimer's disease and related disorders | THE GENERAL HOSPITAL CORPORATION (US) | 2010-12-28 | — | — | US | disclosed |
| US-20100298389-A1 | Novel Imaging Tracers for Early Detection and Treatment of Amyloid Plaques Caused by Alzheimer's Disease and Related Disorders | THE GENERAL HOSPITAL CORPORATION (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100298389-A1 | Novel Imaging Tracers for Early Detection and Treatment of Amyloid Plaques Caused by Alzheimer's Disease and Related Disorders | THE GENERAL HOSPITAL CORPORATION (US) | 2010-11-25 | — | — | US | disclosed |
| WO-2008134618-A2 | NOVEL IMAGING TRACERS FOR EARLY DETECTION AND TREATMENT OF AMYLOID PLAQUES CAUSED BY ALZHEIMER'S DISEASE AND RELATED DISORDERS | THE GENERAL HOSPITAL CORPORATION (US) | 2008-11-06 | — | — | WO | disclosed |
| US-20080267879-A1 | Novel Imaging Tracers for Early Detection and Treatment of Amyloid Plaques Caused by Alzheimer's Disease and Related Disorders | THE GENERAL HOSPITAL CORPORATION (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080267879-A1 | Novel Imaging Tracers for Early Detection and Treatment of Amyloid Plaques Caused by Alzheimer's Disease and Related Disorders | THE GENERAL HOSPITAL CORPORATION (US) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10576171-B2 | Cromolyn derivatives and related methods of imaging and treatment | PSEN1, PSEN2, CROCC | APP 9/4885SULT1A1 2541/4885MAPT 681/4885 |
| US-11801316-B2 | Cromolyn derivatives and related methods of imaging and treatment | PSEN1, PSEN2, CROCC | APP 13/4885SULT1A1 3068/4885MAPT 665/4885 |
| US-11110097-B2 | Combination therapies for the treatment of alzheimer's disease and related disorders | APP, SNCA, MAPT | APP 1/4885SULT1A1 4280/4885MAPT 3/4885 |
| US-20100298389-A1 | Novel Imaging Tracers for Early Detection and Treatment of Amyloid Plaques Caused by Alzheimer's Disease and Related Disorders | APP, MAPT, PSEN1 | APP 1/4885SULT1A1 1481/4885MAPT 2/4885 |
| US-20080267879-A1 | Novel Imaging Tracers for Early Detection and Treatment of Amyloid Plaques Caused by Alzheimer's Disease and Related Disorders | APP, MAPT, PSEN1 | APP 1/4885SULT1A1 1481/4885MAPT 2/4885 |
| US-10413551-B2 | Combination therapies for the treatment of Alzheimer'S disease and related disorders | APP, SNCA, MAPT | APP 1/4885SULT1A1 4280/4885MAPT 3/4885 |
| US-10406164-B2 | Combination therapies for the treatment of Alzheimer's disease and related disorders | APP, SNCA, MAPT | APP 1/4885SULT1A1 4280/4885MAPT 3/4885 |
| US-11666669-B2 | Cromolyn derivatives and related methods of imaging and treatment | PSEN1, PSEN2, CROCC | APP 13/4885SULT1A1 2935/4885MAPT 685/4885 |
| US-20220193087-A1 | COMBINATION THERAPIES FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS | APP, SNCA, MAPT | APP 1/4885SULT1A1 4280/4885MAPT 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.